Drug intelligence / Profile preview

metronidazole + moxifloxacin + rifampin

Development stage
Unknown
Lead developer
Sanofi
Modality
Small Molecules
Administration
Oral
01

Overview

This is a triple antibiotic combination therapy used primarily for treating hidradenitis suppurativa (HS), particularly severe Hurley stage 1. The combination provides broad-spectrum antimicrobial coverage targeting both aerobic and anaerobic bacteria. Metronidazole is a nitroimidazole antibiotic effective against anaerobic bacteria and certain parasites. Moxifloxacin is a fluoroquinolone that inhibits bacterial DNA gyrase and topoisomerase IV. Rifampin is an antibiotic that inhibits bacterial RNA polymerase. The combination has shown efficacy in achieving complete remission in HS patients, particularly those with less severe disease (Hurley stage 1 and 2).

Other names
RMoM
02

Targets

Topo IV (Bacterial Topoisomerase IV)DNA gyraseNeuraminidaserpoB (DNA-directed RNA polymerase subunit beta)

Beyond the preview

Go deeper on metronidazole + moxifloxacin + rifampin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on metronidazole + moxifloxacin + rifampin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call